TRPML1 as a potential therapeutic target for triple-negative breast cancer: a review.

Autor:	Pan Y; Department of Histology and Embryology, College of Basic Medical Sciences, Jilin University, Changchun, Jilin, China., Zhao Q; Department of Cell Biology, College of Basic Medical Sciences, Jilin University, Changchun, Jilin, China., He H; Department of Cell Biology, College of Basic Medical Sciences, Jilin University, Changchun, Jilin, China., Qi Y; First Hospital of Jilin University, Changchun, Jilin, China., Bai Y; First Hospital of Jilin University, Changchun, Jilin, China., Zhao J; Department of Histology and Embryology, College of Basic Medical Sciences, Jilin University, Changchun, Jilin, China., Yang Y; Department of Cell Biology, College of Basic Medical Sciences, Jilin University, Changchun, Jilin, China.
Jazyk:	angličtina
Zdroj:	Frontiers in oncology [Front Oncol] 2023 Dec 13; Vol. 13, pp. 1326023. Date of Electronic Publication: 2023 Dec 13 (Print Publication: 2023).
DOI:	10.3389/fonc.2023.1326023
Abstrakt:	Triple-negative breast cancer (TNBC) is the most refractory subtype of breast cancer, and effective treatments are urgently needed owing to its poor prognosis. Surgery, radiotherapy, and chemotherapy, alone or in combination, are the leading choices for TNBC therapy. Although promising approaches and procedures have emerged, several challenges, such as off-target effects, drug resistance, and severe side effects, remain to be addressed. Recently, transient receptor potential channel mucolipin 1 (TRPML1) has attracted the attention of researchers because its expression has been implicated in numerous diseases, including cancer. TRPML1 regulates biological events and signaling pathways, including autophagic flux, exocytosis, ionic homeostasis, and lysosomal biogenesis, all contributing to tumorigenesis and cancer progression. TRPML1 also functions as a building block for cancer cell growth, mitogenic signaling, priming tissues for metastasis, and activation of transcriptional programs, processes involved in several malignant tumors. This review provides an overview of breast cancer epidemiology and diagnostic techniques and then discusses the existing therapeutics. Additionally, we elaborate on the development of, and associated challenges to, TNBC diagnostics and treatment and the feasibility of TRPML1 as a therapeutic target for TNBC. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Pan, Zhao, He, Qi, Bai, Zhao and Yang.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu